MERUS NV (MRUS) Fundamental Analysis & Valuation

NASDAQ:MRUS • NL0011606264

90 USD
-6.92 (-7.14%)
At close: Dec 29, 2025
88.97 USD
-1.03 (-1.14%)
After Hours: 12/29/2025, 8:07:25 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MRUS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

MRUS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. MRUS has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, MRUS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. MRUS Profitability Analysis

1.1 Basic Checks

  • MRUS had negative earnings in the past year.
  • In the past year MRUS has reported a negative cash flow from operations.
  • MRUS had negative earnings in each of the past 5 years.
  • In the past 5 years MRUS always reported negative operating cash flow.
MRUS Yearly Net Income VS EBIT VS OCF VS FCFMRUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • MRUS has a Return On Assets (-42.15%) which is in line with its industry peers.
  • MRUS has a better Return On Equity (-49.16%) than 66.79% of its industry peers.
Industry RankSector Rank
ROA -42.15%
ROE -49.16%
ROIC N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.91%
ROIC(3y)N/A
ROIC(5y)N/A
MRUS Yearly ROA, ROE, ROICMRUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • MRUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRUS Yearly Profit, Operating, Gross MarginsMRUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MRUS Health Analysis

2.1 Basic Checks

  • MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MRUS has been increased compared to 1 year ago.
  • Compared to 5 years ago, MRUS has more shares outstanding
  • There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MRUS Yearly Shares OutstandingMRUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MRUS Yearly Total Debt VS Total AssetsMRUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 29.22 indicates that MRUS is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 29.22, MRUS belongs to the best of the industry, outperforming 93.21% of the companies in the same industry.
  • MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.22
ROIC/WACCN/A
WACC7.43%
MRUS Yearly LT Debt VS Equity VS FCFMRUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 7.95 indicates that MRUS has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 7.95, MRUS is doing good in the industry, outperforming 74.15% of the companies in the same industry.
  • MRUS has a Quick Ratio of 7.95. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 7.95, MRUS is in the better half of the industry, outperforming 74.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.95
Quick Ratio 7.95
MRUS Yearly Current Assets VS Current LiabilitesMRUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MRUS Growth Analysis

3.1 Past

  • MRUS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.92%.
  • The Revenue has grown by 57.54% in the past year. This is a very strong growth!
  • Measured over the past years, MRUS shows a small growth in Revenue. The Revenue has been growing by 3.03% on average per year.
EPS 1Y (TTM)-36.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.7%
Revenue 1Y (TTM)57.54%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%3.21%

3.2 Future

  • MRUS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.66% yearly.
  • Based on estimates for the next years, MRUS will show a very strong growth in Revenue. The Revenue will grow by 89.98% on average per year.
EPS Next Y-75.87%
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%
EPS Next 5Y26.66%
Revenue Next Year43.37%
Revenue Next 2Y17.82%
Revenue Next 3Y66.5%
Revenue Next 5Y89.98%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MRUS Yearly Revenue VS EstimatesMRUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
MRUS Yearly EPS VS EstimatesMRUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. MRUS Valuation Analysis

4.1 Price/Earnings Ratio

  • MRUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MRUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRUS Price Earnings VS Forward Price EarningsMRUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRUS Per share dataMRUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • MRUS's earnings are expected to decrease with -11.15% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRUS Dividend Analysis

5.1 Amount

  • MRUS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRUS Fundamentals: All Metrics, Ratios and Statistics

MERUS NV

NASDAQ:MRUS (12/29/2025, 8:07:25 PM)

After market: 88.97 -1.03 (-1.14%)

90

-6.92 (-7.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31
Earnings (Next)02-25
Inst Owners91.04%
Inst Owner Change-95.69%
Ins Owners0.22%
Ins Owner Change-2.86%
Market Cap6.83B
Revenue(TTM)56.61M
Net Income(TTM)-381.00M
Analysts70.43
Price Target99.48 (10.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-36.37%
Min EPS beat(2)-83.38%
Max EPS beat(2)10.64%
EPS beat(4)2
Avg EPS beat(4)-12.3%
Min EPS beat(4)-83.38%
Max EPS beat(4)51.7%
EPS beat(8)3
Avg EPS beat(8)-15.65%
EPS beat(12)6
Avg EPS beat(12)-12.87%
EPS beat(16)10
Avg EPS beat(16)1.31%
Revenue beat(2)1
Avg Revenue beat(2)-0.47%
Min Revenue beat(2)-37.2%
Max Revenue beat(2)36.26%
Revenue beat(4)2
Avg Revenue beat(4)55.58%
Min Revenue beat(4)-37.2%
Max Revenue beat(4)232.22%
Revenue beat(8)3
Avg Revenue beat(8)27.5%
Revenue beat(12)6
Avg Revenue beat(12)19.96%
Revenue beat(16)9
Avg Revenue beat(16)16.38%
PT rev (1m)0%
PT rev (3m)5.25%
EPS NQ rev (1m)1.35%
EPS NQ rev (3m)5.18%
EPS NY rev (1m)0.77%
EPS NY rev (3m)4.56%
Revenue NQ rev (1m)-2.85%
Revenue NQ rev (3m)-4.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 120.6
P/FCF N/A
P/OCF N/A
P/B 8.81
P/tB 8.83
EV/EBITDA N/A
EPS(TTM)-5.34
EYN/A
EPS(NY)-5.41
Fwd EYN/A
FCF(TTM)-4.2
FCFYN/A
OCF(TTM)-4.19
OCFYN/A
SpS0.75
BVpS10.22
TBVpS10.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.15%
ROE -49.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.97%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.95
Quick Ratio 7.95
Altman-Z 29.22
F-Score4
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)275.81%
Cap/Depr(5y)194.96%
Cap/Sales(3y)10.83%
Cap/Sales(5y)7.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.7%
EPS Next Y-75.87%
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%
EPS Next 5Y26.66%
Revenue 1Y (TTM)57.54%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%3.21%
Revenue Next Year43.37%
Revenue Next 2Y17.82%
Revenue Next 3Y66.5%
Revenue Next 5Y89.98%
EBIT growth 1Y-60.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.55%
EBIT Next 3Y-2.47%
EBIT Next 5YN/A
FCF growth 1Y-123.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.19%
OCF growth 3YN/A
OCF growth 5YN/A

MERUS NV / MRUS FAQ

Can you provide the ChartMill fundamental rating for MERUS NV?

ChartMill assigns a fundamental rating of 4 / 10 to MRUS.


What is the valuation status for MRUS stock?

ChartMill assigns a valuation rating of 0 / 10 to MERUS NV (MRUS). This can be considered as Overvalued.


Can you provide the profitability details for MERUS NV?

MERUS NV (MRUS) has a profitability rating of 1 / 10.